The AL amyloidosis treatment developer is being taken over AstraZeneca, the parent company of existing investor Alexion.

Alexion, pharmaceutical company AstraZeneca’s rare disease subsidiary, has wholly acquired portfolio company Caelum Biosciences, US-based amyloidosis treatment developer, in a deal sized at up to $500m.

Alexion had previously bought a non-controlling stake in Caelum in January 2019 – before AstraZeneca agreed in December 2020 to purchase the former for $39bn – picking up an option to buy the rest of the Caelum down the line.

The corporate is now exercising the option at a price of $150m upfront, in…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn